ReviewPathogens and global health2015
Killing the hypnozoite--drug discovery approaches to prevent relapse in Plasmodium vivax.
Review in Pathogens and global health, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 1 synthesis or guideline pooled it, 103 citations in OpenAlex.
- Rapid diagnostic tests for Plasmodium vivax malaria in endemic countries.The Cochrane database of systematic reviews · 2020Pooled it
- Estimation of the Antirelapse Efficacy of Tafenoquine, Using Plasmodium vivax Genotyping.The Journal of infectious diseases · 2016Trial
- Tafenoquine: A Breakthrough Option for Babesiosis Treatment.Tropical medicine and infectious disease · 2026Article
- Article
- Innovative Multistage ML-QSAR Models for Malaria: From Data to Discovery.ACS medicinal chemistry letters · 2024Article
- A nanochitosan-D-galactose formulation increases the accumulation of primaquine in the liver.Antimicrobial agents and chemotherapy · 2024Article
- A Drug Repurposing Approach Reveals Targetable Epigenetic Pathways inbioRxiv : the preprint server for biology · 2024Article
- Optimization of Plasmodium vivax infection of colonized Amazonian Anopheles darlingi.Scientific reports · 2023Article
- Ethiopian Plasmodium vivax hypnozoites formation dynamics and their susceptibility to reference antimalarial drugs.BMC infectious diseases · 2023Article
- Putative Contribution of 8-Aminoquinolines to Preventing Recrudescence of Malaria.Tropical medicine and infectious disease · 2023Article
- Optimal Interruption of P. vivax Malaria Transmission Using Mass Drug Administration.Bulletin of mathematical biology · 2023Article
- Erythrocyte miRNA-92a-3p interactions with PfEMP1 as determinants of clinical malaria.Functional & integrative genomics · 2023Article
- A non-canonical sensing pathway mediates Plasmodium adaptation to amino acid deficiency.Communications biology · 2023Article
- Potential Benefits of Lycopene Consumption: Rationale for Using It as an Adjuvant Treatment for Malaria Patients and in Several Diseases.Nutrients · 2022Review
- Targeting malaria parasites inside mosquitoes: ecoevolutionary consequences.Trends in parasitology · 2022Review
- Metabolic, Pharmacokinetic, and Activity Profile of the Liver Stage Antimalarial (RC-12).ACS omega · 2022Article
- Scoping Review of Antimalarial Drug Candidates in Phase I and II Drug Development.Antimicrobial agents and chemotherapy · 2022Article
- Editorial: Antimalarial chemotherapy in the XXIst century.Frontiers in pharmacology · 2022Article
- Probing the distinct chemosensitivity of Plasmodium vivax liver stage parasites and demonstration of 8-aminoquinoline radical cure activity in vitro.Scientific reports · 2021Article
- Chemical Biology Tools To Investigate Malaria Parasites.Chembiochem : a European journal of chemical biology · 2021Review
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The eradication of malaria will only be possible if effective, well-tolerated medicines kill hypnozoites in vivax and ovale malaria, and thus prevent relapses in patients. Despite progress in the 8-aminoquinoline series, with tafenoquine in Phase III showing clear benefits over primaquine, the drug discovery challenge to identify hypnozoiticidal or hypnozoite-activating compounds has been hampered by the dearth of biological tools and assays, which in turn has been limited by the immense scientific and logistical challenges associated with accessing relevant human tissue and sporozoites. This review summarises the existing drug discovery series and approaches concerning the goal to block relapse.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.